This webinar by Dr. Robert Clark describes the in silico design, synthesis, and biological testing of novel antimalarial drug candidates generated by analysis of public HTS data.
Simulations Plus (SLP) Releases MedChem Studio 3.0 and MedChem Designer 2.0
Molecule Design Tools Used in Company’s Malaria Drug Design Project Released
Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling
The dependency of metformin in vivo disposition on the rate and extent of dissolution was studied.
Development of a Robust Cytopathic Effect-Based High-Throughput Screening Assay To Identify Novel Inhibitors of Dengue Virus
We have developed a robust cytopathic effect-based high-throughput screening assay to identify inhibitors of dengue virus (DENV) infection.
Simulations Plus (SLP) Releases GastroPlus™ 8.0
Major New Upgrade Increases Power of Its Best-in-Class Software
Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment
In this review we have examined the status of parameters required by pyrethroid QSAR-PBPK/PD models for assessing health risks.
Simulations Plus Releases ADMET Predictor™ 6.0
Integrates MedChem Designer™ Molecule Drawing, Features Graphical User Interface Improvements and Further Enhanced Molecular Property Predictions
Simulations Plus Announces Next Quarterly Cash Dividend
Company declares cash dividend of $0.05 per share
In Silico Metabolite Prediction Using Artificial Neural Network Ensembles
Drug metabolism plays a crucial role in understanding bioavailability and drug-drug interactions, as well as in the design of prodrugs and in avoiding undesirable toxic metabolites.
Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and In Vivo Relevance
The circadian timing system (CTS) governs the 24-h rhythm of the organism and, hence, also main pathways responsible for drug pharmacokinetics.
Simulations Plus Announces Further Success in Malaria Drug Design Project
Activity Seen Against Both Drug-Sensitive and Drug-Resistant Strains
Simulations Plus Reports Second Quarter and First Six Months FY2012 Financial Results
Net sales increase 6.4% to record for any quarter of $2.789 million; first half net income up 22.7% to $1.810 million
Simulations Plus Sets Date for 2nd Quarter 2012 Earnings Release and Conference Call
Conference Call to Be on Tuesday, April 10, at 4:15 PM ET
MAA Found Math
Each week, the Mathematical Association of America website posts a new math-related photo that was submitted by an MAA member. The photo reposted here is a decorative Venn Diagram on a ceiling light that was featured on May 31, 2011. The photographer was Joy Hsiao of Brooklyn Technical High School. Visit the MAA Found Math gallery to view more of these fascinating photos.
Simulations Plus Announces Preliminary Success in Malaria Drug Design Project
New Molecule Has Excellent Activity Against Malaria Parasite
Modeling of Furosemide in DILIsym™ Model Reveals Testable Hypotheses about Hepatotoxicity Mechanisms
A predictive, quantitative, mathematical model (DILIsym™) is under development as a public-private initiative based on the physiological processes involved in drug-induced liver injury. The model includes…
Simulations Plus Buys out Royalty Agreement
Company Now Owns IP in ADMET Predictor™ Enslein Metabolism Module
In Silico Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate
The aim of this work was to extrapolate in vitro and preclinical animal data to simulate the pharmacokinetic parameters of UK-343,664, a P-glycoprotein (P-gp) and CYP3A4 substrate, in human.
Simulations Plus Reports Record Second Quarter FY2012 Preliminary Revenues
Net sales increase to new record for any quarter of $2.789 million, up 24% sequentially and 6.4% compared to 2QFY11